{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:11:52Z","timestamp":1790255512280,"version":"4.1.0"},"reference-count":113,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Multiple myeloma (MM) is a genetically heterogeneous disease, in which the process of tumorigenesis begins and progresses through the appearance and accumulation of a tangle of genomic aberrations. Several are the mechanisms of DNA damage in MM, varying from single nucleotide substitutions to complex genomic events. The timing of appearance of aberrations is well studied due to the natural history of the disease, that usually progress from pre-malignant to malignant phase. Different kinds of aberrations carry different prognostic significance and have been associated with drug resistance in some studies. Certain genetic events are well known to be associated with prognosis and are incorporated in risk evaluation in MM at diagnosis in the revised International Scoring System (R-ISS). The significance of some other aberrations needs to be further explained. Since now, few phase 3 randomized trials included analysis on patient\u2019s outcomes according to genetic risk, and further studies are needed to obtain useful data to stratify the choice of initial and subsequent treatment in MM.<\/jats:p>","DOI":"10.3390\/genes11121453","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:09:40Z","timestamp":1607026180000},"page":"1453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-7645","authenticated-orcid":false,"given":"Mariarosaria","family":"Sessa","sequence":"first","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S.Anna, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S.Anna, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-5773","authenticated-orcid":false,"given":"Maurizio","family":"Cavallari","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S.Anna, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-5190","authenticated-orcid":false,"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S.Anna, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S.Anna, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells","volume":"78","author":"Spaan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0238-0","article-title":"Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma","volume":"9","author":"Coffey","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rasche, L., Chavan, S.S., Stephens, O.W., Patel, P.H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., and Wardell, C. (2017). Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun., 8.","DOI":"10.1038\/s41467-017-00296-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the Impact of Structural Variants in Multiple Myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2017.08.004","article-title":"Detection of complex genomic signatures associated with risk in plasma cell disorders","volume":"218\u2013219","author":"Berry","year":"2017","journal-title":"Cancer Genet."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Maura, F., Bolli, N., Angelopoulos, N., Dawson, K.J., Leongamornlert, D., Martincorena, I., Mitchell, T.J., Fullam, A., Gonzales, S., and Szalat, R. (2019). Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun., 10.","DOI":"10.1038\/s41467-019-11680-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.12.005","article-title":"Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma","volume":"76","author":"Kaur","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Walker, B.A., Wardell, C.P., Murison, A., Boyle, E.M., Begum, D.B., Dahir, N.M., Proszek, P.Z., Melchor, L., Pawlyn, C., and Kaiser, M.F. (2015). APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun., 6.","DOI":"10.1038\/ncomms7997"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","article-title":"Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5808\/GI.2017.15.3.87","article-title":"Chromothripsis in Treatment Resistance in Multiple Myeloma","volume":"15","author":"Lee","year":"2017","journal-title":"Genomics Inform."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res."},{"key":"ref_24","first-page":"1","article-title":"Deciphering the chronology of copy number alterations in Multiple Myeloma","volume":"9","author":"Minvielle","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107, K.K., Escure, G., Demonchy, J., Willaume, A., Van de Wyngaert, Z., Farhat, M., Chauvet, P., Facon, T., Quesnel, B., and Manier, S. (2019). Deregulation and targeting of TP53 pathway in multiple myeloma. Front. Oncol., 9.","DOI":"10.3389\/fonc.2018.00665"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Eveillard","year":"2010","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/gcc.20899","article-title":"The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy","volume":"50","author":"Boyd","year":"2011","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.18632\/oncotarget.7241","article-title":"Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: An italian cohort study and overview of the literature","volume":"7","author":"Lionetti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1038\/bcj.2017.76","article-title":"Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival","volume":"7","author":"Chin","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4939-7780-2_15","article-title":"Genes, proteins, and biological pathways preventing chromothripsis","volume":"1769","author":"Poot","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.critrevonc.2019.07.016","article-title":"Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies","volume":"142","author":"Berry","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13039-020-0470-0","article-title":"Chromoanagenesis: A piece of the macroevolution scenario","volume":"13","author":"Pellestor","year":"2020","journal-title":"Mol. Cytogenet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.V80.1.203.203","article-title":"Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia","volume":"80","author":"Onodera","year":"1992","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1111\/bjh.16547","article-title":"Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow","volume":"189","author":"Petrackova","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Li","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., Jenner, M.W., Boyd, K.D., Johnson, D.C., Gonzalez, D., Dagrada, G.P., and Protheroe, R.K.M. (2010). A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 116.","DOI":"10.1182\/blood-2010-04-279596"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Dewald","year":"2003","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Intergroupe Francophone du My\u00e9lome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Gerson","year":"2001","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous Mutations Activate the Noncanonical NF-\u03baB Pathway in Multiple Myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00005-016-0442-6","article-title":"Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma","volume":"64","author":"Butrym","year":"2016","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"ref_51","first-page":"1","article-title":"Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide","volume":"9","author":"Huang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"ref_57","first-page":"4546","article-title":"14q32 Translocations and Monosomy 13 Observed in Monoclonal Gammopathy of Undetermined Significance Delineate a Multistep Process for the Oncogenesis of Multiple Myeloma 1","volume":"59","author":"Facon","year":"1999","journal-title":"CANCER Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Fenton","year":"2007","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cell.2015.12.050","article-title":"Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair","volume":"164","author":"Haradhvala","year":"2016","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1749-6632.2012.06614.x","article-title":"Creative deaminases, self-inflicted damage, and genome evolution","volume":"1267","author":"Conticello","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Lee","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature14493","article-title":"Chromothripsis from DNA damage in micronuclei","volume":"522","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Fontana, M.C., Marconi, G., Milosevic Feenstra, J.D., Fonzi, E., Papayannidis, C., Ghelli Luserna di Ror\u00e0, A., Padella, A., Solli, V., Franchini, E., and Ottaviani, M. (2018). Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. Leukemia.","DOI":"10.1038\/leu.2017.351"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2013.02.023","article-title":"Criteria for inference of chromothripsis in cancer genomes","volume":"152","author":"Korbel","year":"2013","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cell.2015.11.054","article-title":"Chromothripsis and Kataegis Induced by Telomere Crisis","volume":"163","author":"Maciejowski","year":"2015","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gde.2020.02.009","article-title":"Chromothripsis and telomere crisis: Engines of genome instability","volume":"60","author":"Dewhurst","year":"2020","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cell.2011.07.042","article-title":"Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements","volume":"146","author":"Liu","year":"2011","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.cell.2007.11.037","article-title":"A DNA Replication Mechanism for Generating Nonrecurrent Rearrangements Associated with Genomic Disorders","volume":"131","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hastings, P.J., Ira, G., and Lupski, J.R. (2009). A Microhomology-Mediated Break-Induced Replication Model for the Origin of Human Copy Number Variation. PLoS Genet., 5.","DOI":"10.1371\/journal.pgen.1000327"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-018-0534-z","article-title":"Nuclear envelope assembly defects link mitotic errors to chromothripsis","volume":"561","author":"Liu","year":"2018","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.gde.2012.01.009","article-title":"Replication stress and mechanisms of CNV formation","volume":"22","author":"Arlt","year":"2012","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccr.2013.04.025","article-title":"Chromoplexy: A New Category of Complex Rearrangements in the Cancer Genome","volume":"23","author":"Shen","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1101\/gad.229559.113","article-title":"Chromothripsis and beyond: Rapid genome evolution from complex chromosomal rearrangements","volume":"27","author":"Zhang","year":"2013","journal-title":"Genes Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13039-019-0415-7","article-title":"Chromoanagenesis: Cataclysms behind complex chromosomal rearrangements","volume":"12","author":"Pellestor","year":"2019","journal-title":"Mol. Cytogenet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2018.11.001","article-title":"The molecular origins and pathophysiological consequences of micronuclei: New insights into an age-old problem","volume":"779","author":"Guo","year":"2019","journal-title":"Mutat. Res.-Rev. Mutat. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"JCO2000461","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group","volume":"38","author":"Samur","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clon.2018.01.001","article-title":"Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma\u2014Introducing the PERM Trial","volume":"30","author":"Yip","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Paner, A., Patel, P., and Dhakal, B. (2020). The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev., 41.","DOI":"10.1016\/j.blre.2019.100643"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimaraes, J.E., and Vasconcelos, M.H. (2020). Multiple myeloma: Available therapies and causes of drug resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2011-01-327262","article-title":"MEK and MAF in myeloma therapy","volume":"117","author":"Popovic","year":"2011","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Attal","year":"2007","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"P53 Gene Deletion Detected By Fluorescence in Situ Hybridization Is an Adverse Prognostic Factor for Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A mult","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomise","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/12\/1453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:55Z","timestamp":1760179255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/12\/1453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":113,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["genes11121453"],"URL":"https:\/\/doi.org\/10.3390\/genes11121453","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}